Seroatlas · Human Serome Atlas

FAT2

Protocadherin Fat 2

Also known as: CDHF8, CDHR9, FAT2_HUMAN, HFAT2, MEGF1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9NYQ8
Gene
FAT2
Ensembl
ENSG00000086570
Chromosome
5
Canonical length
4349 aa
Protein class
Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins
Subcellular location
Vesicles
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene is the second identified human homolog of the Drosophila fat gene, which encodes a tumor suppressor essential for controlling cell proliferation during Drosophila development. The gene product is a member of the cadherin superfamily, a group of integral membrane proteins characterized by the presence of cadherin-type repeats. In addition to containing 34 tandem cadherin-type repeats, the gene product has two epidermal growth factor (EGF)-like repeats and one laminin G domain. This protein most likely functions as a cell adhesion molecule, controlling cell proliferation and playing an important role in cerebellum development. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

4349 residues, UniProt reviewed canonical sequence.

>Q9NYQ8|FAT2
     1  MTIALLGFAI FLLHCATCEK PLEGILSSSA WHFTHSHYNA TIYENSSPKT YVESFEKMGI
    61  YLAEPQWAVR YRIISGDVAN VFKTEEYVVG NFCFLRIRTK SSNTALLNRE VRDSYTLIIQ
   121  ATEKTLELEA LTRVVVHILD QNDLKPLFSP PSYRVTISED MPLKSPICKV TATDADLGQN
   181  AEFYYAFNTR SEMFAIHPTS GVVTVAGKLN VTWRGKHELQ VLAVDRMRKI SEGNGFGSLA
   241  ALVVHVEPAL RKPPAIASVV VTPPDSNDGT TYATVLVDAN SSGAEVESVE VVGGDPGKHF
   301  KAIKSYARSN EFSLVSVKDI NWMEYLHGFN LSLQARSGSG PYFYSQIRGF HLPPSKLSSL
   361  KFEKAVYRVQ LSEFSPPGSR VVMVRVTPAF PNLQYVLKPS SENVGFKLNA RTGLITTTKL
   421  MDFHDRAHYQ LHIRTSPGQA STVVVIDIVD CNNHAPLFNR SSYDGTLDEN IPPGTSVLAV
   481  TATDRDHGEN GYVTYSIAGP KALPFSIDPY LGIISTSKPM DYELMKRIYT FRVRASDWGS
   541  PFRREKEVSI FLQLRNLNDN QPMFEEVNCT GSIRQDWPVG KSIMTMSAID VDELQNLKYE
   601  IVSGNELEYF DLNHFSGVIS LKRPFINLTA GQPTSYSLKI TASDGKNYAS PTTLNITVVK
   661  DPHFEVPVTC DKTGVLTQFT KTILHFIGLQ NQESSDEEFT SLSTYQINHY TPQFEDHFPQ
   721  SIDVLESVPI NTPLARLAAT DPDAGFNGKL VYVIADGNEE GCFDIELETG LLTVAAPLDY
   781  EATNFYILNV TVYDLGTPQK SSWKLLTVNV KDWNDNAPRF PPGGYQLTIS EDTEVGTTIA
   841  ELTTKDADSE DNGRVRYTLL SPTEKFSLHP LTGELVVTGH LDRESEPRYI LKVEARDQPS
   901  KGHQLFSVTD LIITLEDVND NSPQCITEHN RLKVPEDLPP GTVLTFLDAS DPDLGPAGEV
   961  RYVLMDGAHG TFRVDLMTGA LILERELDFE RRAGYNLSLW ASDGGRPLAR RTLCHVEVIV
  1021  LDVNENLHPP HFASFVHQGQ VQENSPSGTQ VIVVAAQDDD SGLDGELQYF LRAGTGLAAF
  1081  SINQDTGMIQ TLAPLDREFA SYYWLTVLAV DRGSVPLSSV TEVYIEVTDA NDNPPQMSQA
  1141  VFYPSIQEDA PVGTSVLQLD AWDPDSSSKG KLTFNITSGN YMGFFMIHPV TGLLSTAQQL
  1201  DRENKDEHIL EVTVLDNGEP SLKSTSRVVV GILDVNDNPP IFSHKLFNVR LPERLSPVSP
  1261  GPVYRLVASD LDEGLNGRVT YSIEDSDEEA FSIDLVTGVV SSSSTFTAGE YNILTIKATD
  1321  SGQPPLSASV RLHIEWIPWP RPSSIPLAFD ETYYSFTVME TDPVNHMVGV ISVEGRPGLF
  1381  WFNISGGDKD MDFDIEKTTG SIVIARPLDT RRRSNYNLTV EVTDGSRTIA TQVHIFMIAN
  1441  INHHRPQFLE TRYEVRVPQD TVPGVELLRV QAIDQDKGKS LIYTIHGSQD PGSASLFQLD
  1501  PSSGVLVTVG KLDLGSGPSQ HTLTVMVRDQ EIPIKRNFVW VTIHVEDGNL HPPRFTQLHY
  1561  EASVPDTIAP GTELLQVRAM DADRGVNAEV HYSLLKGNSE GFFNINALLG IITLAQKLDQ
  1621  ANHAPHTLTV KAEDQGSPQW HDLATVIIHV YPSDRSAPIF SKSEYFVEIP ESIPVGSPIL
  1681  LVSAMSPSEV TYELREGNKD GVFSMNSYSG LISTQKKLDH EKISSYQLKI RGSNMAGAFT
  1741  DVMVVVDIID ENDNAPMFLK STFVGQISEA APLYSMIMDK NNNPFVIHAS DSDKEANSLL
  1801  VYKILEPEAL KFFKIDPSMG TLTIVSEMDY ESMPSFQFCV YVHDQGSPVL FAPRPAQVII
  1861  HVRDVNDSPP RFSEQIYEVA IVGPIHPGME LLMVRASDED SEVNYSIKTG NADEAVTIHP
  1921  VTGSISVLNP AFLGLSRKLT IRASDGLYQD TALVKISLTQ VLDKSLQFDQ DVYWAAVKEN
  1981  LQDRKALVIL GAQGNHLNDT LSYFLLNGTD MFHMVQSAGV LQTRGVAFDR EQQDTHELAV
  2041  EVRDNRTPQR VAQGLVRVSI EDVNDNPPKF KHLPYYTIIQ DGTEPGDVLF QVSATDEDLG
  2101  TNGAVTYEFA EDYTYFRIDP YLGDISLKKP FDYQALNKYH LKVIARDGGT PSLQSEEEVL
  2161  VTVRNKSNPL FQSPYYKVRV PENITLYTPI LHTQARSPEG LRLIYNIVEE EPLMLFTTDF
  2221  KTGVLTVTGP LDYESKTKHV FTVRATDTAL GSFSEATVEV LVEDVNDNPP TFSQLVYTTS
  2281  ISEGLPAQTP VIQLLASDQD SGRNRDVSYQ IVEDGSDVSK FFQINGSTGE MSTVQELDYE
  2341  AQQHFHVKVR AMDKGDPPLT GETLVVVNVS DINDNPPEFR QPQYEANVSE LATCGHLVLK
  2401  VQAIDPDSRD TSRLEYLILS GNQDRHFFIN SSSGIISMFN LCKKHLDSSY NLRVGASDGV
  2461  FRATVPVYIN TTNANKYSPE FQQHLYEAEL AENAMVGTKV IDLLAIDKDS GPYGTIDYTI
  2521  INKLASEKFS INPNGQIATL QKLDRENSTE RVIAIKVMAR DGGGRVAFCT VKIILTDEND
  2581  NPPQFKASEY TVSIQSNVSK DSPVIQVLAY DADEGQNADV TYSVNPEDLV KDVIEINPVT
  2641  GVVKVKDSLV GLENQTLDFF IKAQDGGPPH WNSLVPVRLQ VVPKKVSLPK FSEPLYTFSA
  2701  PEDLPEGSEI GIVKAVAAQD PVIYSLVRGT TPESNKDGVF SLDPDTGVIK VRKPMDHEST
  2761  KLYQIDVMAH CLQNTDVVSL VSVNIQVGDV NDNRPVFEAD PYKAVLTENM PVGTSVIQVT
  2821  AIDKDTGRDG QVSYRLSADP GSNVHELFAI DSESGWITTL QELDCETCQT YHFHVVAYDH
  2881  GQTIQLSSQA LVQVSITDEN DNAPRFASEE YRGSVVENSE PGELVATLKT LDADISEQNR
  2941  QVTCYITEGD PLGQFGISQV GDEWRISSRK TLDREHTAKY LLRVTASDGK FQASVTVEIF
  3001  VLDVNDNSPQ CSQLLYTGKV HEDVFPGHFI LKVSATDLDT DTNAQITYSL HGPGAHEFKL
  3061  DPHTGELTTL TALDRERKDV FNLVAKATDG GGRSCQADIT LHVEDVNDNA PRFFPSHCAV
  3121  AVFDNTTVKT PVAVVFARDP DQGANAQVVY SLPDSAEGHF SIDATTGVIR LEKPLQVRPQ
  3181  APLELTVRAS DLGTPIPLST LGTVTVSVVG LEDYLPVFLN TEHSVQVPED APPGTEVLQL
  3241  ATLTRPGAEK TGYRVVSGNE QGRFRLDART GILYVNASLD FETSPKYFLS IECSRKSSSS
  3301  LSDVTTVMVN ITDVNEHRPQ FPQDPYSTRV LENALVGDVI LTVSATDEDG PLNSDITYSL
  3361  IGGNQLGHFT IHPKKGELQV AKALDREQAS SYSLKLRATD SGQPPLHEDT DIAIQVADVN
  3421  DNPPRFFQLN YSTTVQENSP IGSKVLQLIL SDPDSPENGP PYSFRITKGN NGSAFRVTPD
  3481  GWLVTAEGLS RRAQEWYQLQ IQASDSGIPP LSSLTSVRVH VTEQSHYAPS ALPLEIFITV
  3541  GEDEFQGGMV GKIHATDRDP QDTLTYSLAE EETLGRHFSV GAPDGKIIAA QGLPRGHYSF
  3601  NVTVSDGTFT TTAGVHVYVW HVGQEALQQA MWMGFYQLTP EELVSDHWRN LQRFLSHKLD
  3661  IKRANIHLAS LQPAEAVAGV DVLLVFEGHS GTFYEFQELA SIITHSAKEM EHSVGVQMRS
  3721  AMPMVPCQGP TCQGQICHNT VHLDPKVGPT YSTARLSILT PRHHLQRSCS CNGTATRFSG
  3781  QSYVRYRAPA ARNWHIHFYL KTLQPQAILL FTNETASVSL KLASGVPQLE YHCLGGFYGN
  3841  LSSQRHVNDH EWHSILVEEM DASIRLMVDS MGNTSLVVPE NCRGLRPERH LLLGGLILLH
  3901  SSSNVSQGFE GCLDAVVVNE EALDLLAPGK TVAGLLETQA LTQCCLHSDY CSQNTCLNGG
  3961  KCSWTHGAGY VCKCPPQFSG KHCEQGRENC TFAPCLEGGT CILSPKGASC NCPHPYTGDR
  4021  CEMEARGCSE GHCLVTPEIQ RGDWGQQELL IITVAVAFII ISTVGLLFYC RRCKSHKPVA
  4081  MEDPDLLARS VGVDTQAMPA IELNPLSASS CNNLNQPEPS KASVPNELVT FGPNSKQRPV
  4141  VCSVPPRLPP AAVPSHSDNE PVIKRTWSSE EMVYPGGAMV WPPTYSRNER WEYPHSEVTQ
  4201  GPLPPSAHRH STPVVMPEPN GLYGGFPFPL EMENKRAPLP PRYSNQNLED LMPSRPPSPR
  4261  ERLVAPCLNE YTAISYYHSQ FRQGGGGPCL ADGGYKGVGM RLSRAGPSYA VCEVEGAPLA
  4321  GQGQPRVPPN YEGSDMVESD YGSCEEVMF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FAT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0
Highest tissue expression
223 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 223 nTPM
  • skin: 53 nTPM
  • esophagus: 49 nTPM
  • vagina: 24 nTPM
  • cervix: 21 nTPM
  • testis: 13 nTPM

Single-cell type

  • ocular epithelial cells: 124 nCPM
  • brain excitatory neurons: 110 nCPM
  • suprabasal keratinocytes: 110 nCPM
  • respiratory basal cells: 108 nCPM
  • basal keratinocytes: 87 nCPM
  • prostatic hillock cells: 85 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebellum: 234 nTPM
  • pons: 38 nTPM
  • medulla oblongata: 18 nTPM
  • cerebral cortex: 13 nTPM
  • basal ganglia: 11 nTPM
  • midbrain: 8 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FAT2.

Disease | AllUniProt

Conditions FAT2 is implicated in, by any mechanism.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 1,564 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Spinocerebellar ataxia 45

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.51
gnomAD pLI
0
gnomAD missense Z
0.72
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FAT2 as an antibody target. Whether an autoantibody or antibody against FAT2 could matter depends on whether native FAT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FAT2 is annotated at the cell surface, where native FAT2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label FAT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FAT2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...